Johnson & Johnson Reportedly Ordered To Pay $966M To Family Of Woman Who Died Of Rare Cancer Allegedly Associated With Its Talc

According to a Reuters report, a Los Angeles Jury has ordered the company to pay $16 million in compensatory damages and $950 million in punitive damages.

📰 Article Image

In this photo illustration, a Johnson & Johnson logo seen displayed on a monitor. (Photo Illustration by Valera Golovniov/SOPA Images/LightRocket via Getty Images)

👤

Anan Ashraf · Stocktwits

Published Oct 7, 2025, 5:44 PM

JNJ

Johnson & Johnson (JNJ) has reportedly been ordered to pay $966 million to the family of a woman who died from a rare form of cancer called mesothelioma after a jury found the company liable.

Mae Moore died in 2021, and her family subsequently sued the company, claiming that Johnson & Johnson’s talc baby powder products contained asbestos fibers that caused her rare cancer.

Reuters reported that a Los Angeles Jury has ordered the company to pay $16 million in compensatory damages and $950 million in punitive damages. The verdict could be reduced on appeal, the report added. J&J stopped selling talc-based baby powder in the U.S. in 2020.

JNJ is reportedly planning to appeal immediately, calling the verdict "egregious and unconstitutional." Shares of the company dropped 0.3% at the time of writing. On Stocktwits, retail sentiment around JNJ stock fell from ‘extremely bullish’ to ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘normal’ levels.

📷
JNJ's Sentiment Meter and Message Volume as of 1:27 p.m. ET on Oct. 07, 2025 | Source: Stocktwits

In April, a Texas judge dismissed J&J's attempt to settle class action lawsuits related to claims of talcum powder causing ovarian cancer via a $10 billion Chapter 11 filing. The company had aimed to settle claims against its subsidiary, Red River Talc, through the bankruptcy process. It marked the company’s third attempt to resolve talc-related litigation through bankruptcy proceedings.

Separately, Citi raised the price target on JNJ to $213 from $200 on Tuesday, while maintaining a ‘Buy’ rating on the shares.

JNJ stock is up by 30% this year and by about 18% over the past 12 months. 

Read also: STAAR Surgical’s Long-Term Shareholder Says Proposed Deal With Alcon Undervalues The Company

For updates and corrections, email newsroom[at]stocktwits[dot]com.